Related Experiment Video
Updated: May 28, 2025
The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
Published on: November 30, 2016
Anamorelin as a Therapeutic Option for Cancer Cachexia in Advanced Pancreatic Cancer: A Case Report Demonstrating
Motoyasu Kan1,2, Yoshiki Ogane1, Kazuki Watabe1
1Department of Gastroenterology, Graduate School of Medicine, Chiba University, Japan.
Abstract:
Cancer cachexia, which is characterized by weight loss and muscle weakness, is common in patients with pancreatic cancer. Anamorelin, a ghrelin receptor agonist, has shown potential for the management of cachexia in various cancers. We herein report a 64-year-old man with unresectable pancreatic cancer who experienced significant weight gain with anamorelin, allowing for continued chemotherapy and an improved quality of life. Despite disease progression, his response suggests the potential utility of anamorelin as a supportive therapy. Cachexia's complex metabolic changes make treatment difficult; however, anamorelin's appetite and weight gain effects highlight its possible role in managing cachexia in pancreatic cancer. Therefore, further research is required in this regard.
More Related Videos
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Related Concept Videos
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...